Company: MYGN
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0000899923-25-000086
Chunk: 13

Company: MYRIAD GENETICS INC
Filing Date: 2025-08-06
Form: 10-Q
Item: Part I, Item 1
Chunk 13
---
 debt securities, net of tax— 0.1 — 0.1 Change in foreign currency translation adjustment, net of tax0.5 0.1 0.7 (1.0)Reclassification of cumulative translation adjustment to income upon sale or liquidation of certain foreign entities, net of tax— — — 0.7 Comprehensive loss$(330.0)$(36.5)$(329.9)$(62.9)

See accompanying notes to Condensed Consolidated Financial Statements.

6

MYRIAD GENETICS, INC.

AND SUBSIDIARIES

Condensed Consolidated Statements of Stockholders’ Equity (unaudited)

(in millions)

CommonstockAdditionalpaid-incapitalAccumulatedothercomprehensivelossAccumulateddeficitMyriad Genetics, Inc.Stockholders’equityBALANCES AT DECEMBER 31, 2023$0.9 $1,415.5 $(3.7)$(629.5)$783.2 Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax— (8.7)— — (8.7)Stock-based compensation expense— 12.0 — — 12.0 Net loss— — — (26.0)(26.0)Other comprehensive loss, net of tax— — (0.5)— (0.5)BALANCES AT MARCH 31, 2024$0.9 $1,418.8 $(4.2)$(655.5)$760.0 Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax— 2.5 — — 2.5 Stock-based compensation expense— 14.5 — — 14.5 Net loss— — — (36.7)(36.7)Other comprehensive income, net of tax— — 0.2 — 0.2 BALANCES AT JUNE 30, 2024$0.9 $1,435.8 $(4.0)$(692.2)$740.5 BALANCES AT DECEMBER 31, 2024$0.9 $1,457.8 $(0.8)$(756.8)$701.1 Issuance of